Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
541 to 560 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Next-generation sequencing improves agreement and accuracy in the diagnosis of Spitz and spitzoid melanocytic lesions. | J Cutan Pathol | 2022 | 35793166 | PubTator, text mining | PubMed |
| Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. | J Thorac Oncol | 2022 | 35788405 | PubTator, text mining | PubMed |
| Liquid First Is "Solid" in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing. | Front Oncol | 2022 | 35785173 | PubTator, text mining | PubMed |
| Applications and Achievements of Single-Cell Sequencing in Gastrointestinal Cancer. | Front Oncol | 2022 | 35785171 | PubTator, text mining | PubMed |
| NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. | Pathologica | 2022 | 35775706 | PubTator, text mining | PubMed |
| Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. | Front Oncol | 2022 | 35774122 | PubTator, text mining | PubMed |
| Perisciatic Nerve Dexmedetomidine Alleviates Spinal Oxidative Stress and Improves Peripheral Mitochondrial Dynamic Equilibrium in a Neuropathic Pain Mouse Model in an AMPK-Dependent Manner. | Dis Markers | 2022 | 35769812 | PubTator, text mining | PubMed |
| RET kinase inhibitors for RET-altered thyroid cancers. | Ther Adv Med Oncol | 2022 | 35756966 | PubTator, text mining | PubMed |
| Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report. | J Int Med Res | 2022 | 35751411 | PubTator, text mining | PubMed |
| The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). | Clin Pract | 2022 | 35735665 | PubTator, text mining | PubMed |
| Phosphoregulation of Kinesins Involved in Long-Range Intracellular Transport. | Front Cell Dev Biol | 2022 | 35721476 | PubTator, text mining | PubMed |
| ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report. | Diagn Pathol | 2022 | 35718773 | PubTator, text mining | PubMed |
| A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-PDGFRA rearrangement-Case report and literature review. | Medicine (Baltimore) | 2022 | 35713428 | PubTator, text mining | PubMed |
| Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report. | JTO Clin Res Rep | 2022 | 35711719 | PubTator, text mining | PubMed |
| Phasing analysis of lung cancer genomes using a long read sequencer. | Nat Commun | 2022 | 35710642 | PubTator, text mining | PubMed |
| An approach to quantitate maternal transcripts localized in sea urchin egg cortex using RT-qPCR with accurate normalization. | PLoS One | 2022 | 35709154 | PubTator, text mining | PubMed |
| Research Progress on RET Fusion in Non-Small-Cell Lung Cancer. | Front Oncol | 2022 | 35707347 | PubTator, text mining | PubMed |
| Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations. | J Thorac Dis | 2022 | 35693600 | PubTator, text mining | PubMed |
| Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer. | Transl Lung Cancer Res | 2022 | 35693289 | PubTator, text mining | PubMed |
| The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research. | Front Oncol | 2022 | 35692799 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=28